Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse: British Journal of Haematology

V. Montefusco, A. Corso, M. Galli, I. Ardoino, S. Pezzatti, C. Carniti, F. Patriarca, F. Gherlinzoni, R. Zambello, S. Sammassimo, M. Marcatti, A. Nozza, C. Crippa, A.M. Cafro, L. Baldini, P. Corradini

Research output: Contribution to journalArticlepeer-review

Abstract

Bortezomib- and lenalidomide-containing regimens are well-established therapies in multiple myeloma (MM). However, despite their extensive use, head-to-head comparisons have never been performed. Therefore, we compared bortezomib and lenalidomide in fixed-duration therapies. In this open-label, phase III study, we randomized MM patients at first relapse to receive either nine cycles of bortezomib plus cyclophosphamide plus dexamethasone (VCD) or lenalidomide plus cyclophosphamide plus dexamethasone (RCD). The primary endpoint was achievement of a very good partial response (VGPR) or better at six weeks after nine treatment cycles. From March 2011 to February 2015, 155 patients were randomized. VGPR or better was achieved by 12 patients (15%) in the VCD arm and 14 patients (18%) in the RCD arm (P = 0·70). Median progression-free survival (PFS) was 16·3 (95% CI: 12·1–22·4) with VCD and 18·6 months (95% CI: 14·7–25·5) with RCD, and the two-year overall survival (OS) was 75% (95% CI: 66–86%) and 74% (95% CI: 64–85%) respectively. In subgroup analyses, no differences in PFS were observed in bortezomib- and lenalidomide-naïve patients, nor in patients who received a bortezomib-based regimen in first line. Adverse events were consistent with the well-established safety profiles of both drugs. Bortezomib and lenalidomide treatments were equally effective in terms of depth of response, PFS, and OS in MM patients at first relapse. © 2019 British Society for Haematology and John Wiley & Sons Ltd
Original languageEnglish
Pages (from-to)907-917
Number of pages11
JournalBr. J. Haematol.
Volume188
Issue number6
DOIs
Publication statusPublished - 2020

Keywords

  • bortezomib
  • lenalidomide
  • myeloma
  • CD4 antigen
  • CD56 antigen
  • CD8 antigen
  • cyclophosphamide
  • dexamethasone
  • immunoglobulin A
  • immunoglobulin M
  • antineoplastic agent
  • adult
  • aged
  • Article
  • blood toxicity
  • bone marrow toxicity
  • cancer combination chemotherapy
  • cancer recurrence
  • CD3+ T lymphocyte
  • CD4+ T lymphocyte
  • CD8+ T lymphocyte
  • comparative study
  • controlled study
  • drug cost
  • drug efficacy
  • drug response
  • drug safety
  • drug withdrawal
  • female
  • human
  • human cell
  • immune reconstitution
  • immunoglobulin blood level
  • immunophenotyping
  • lymphocyte count
  • major clinical study
  • male
  • median survival time
  • multicenter study
  • multiple cycle treatment
  • multiple myeloma
  • neutropenia
  • open study
  • overall survival
  • patient compliance
  • peripheral neuropathy
  • phase 3 clinical trial
  • priority journal
  • progression free survival
  • randomized controlled trial
  • middle aged
  • recurrent disease
  • treatment outcome
  • Antineoplastic Combined Chemotherapy Protocols
  • Bortezomib
  • Cyclophosphamide
  • Dexamethasone
  • Female
  • Humans
  • Lenalidomide
  • Male
  • Middle Aged
  • Multiple Myeloma
  • Recurrence
  • Treatment Outcome

Fingerprint Dive into the research topics of 'Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse: British Journal of Haematology'. Together they form a unique fingerprint.

Cite this